Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …

Circumvention of cancer drug resistance is one of the major investigations in nanomedicine.
In this regard, nanotechnology-based drug delivery has offered various implications …

The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

Gemcitabine (2′, 2′-difluoro 2′-deoxycytidine, dFdC) is the most important cytidine
analogue developed since cytosine arabinoside (Ara-C). The evidence of its potent …

Nucleoside transport in humans is mediated by members of two unrelated protein families,
the SLC28 family of cation-linked concentrative nucleoside transporters (CNTs) and the …

The International Transporter Consortium (ITC) has recently described seven transporters of
particular relevance to drug development. Based on the second ITC transporter workshop in …

Equilibrative nucleoside transporters (ENTs) are polytopic integral membrane proteins that
mediate the transport of nucleosides, nucleobases, and therapeutic analogs. The best …

Background: This multicentre randomised phase III trial was designed to determine whether
adjuvant chemotherapy with gemcitabine improves the outcomes of patients with resected …